Tara Sanft Discusses Advancements in HER2+ Treatments

Video

Tara Sanft, MD, of Smilow Cancer Hospital at Yale-New Haven Hospital describes some of the new treatments for patients with HER2+ breast cancer.

Among the drugs available, Sanft explains that pertuzumab used along with trastuzumab and chemotherapy, produces a better chance that the patient will have a pathologic complete response (pCR). Patients who reach pCR go on to have a better prognosis.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
Related Content
Anatomical image of a person with a breast tumor

T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

Tim Cortese
June 11th 2025
Article

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

AI-generated graphic of cancer cells

T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

Chris Ryan
June 2nd 2025
Article

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Line illustration of a breast

Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC

Kristi Rosa
May 31st 2025
Article

Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

Anatomical rendering of a breast with a tumor

Vepdegestrant Increases PFS in ESR1-Mutated ER+/HER2- Breast Cancer

Caroline Seymour
May 31st 2025
Article

Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.